Search

A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. 

… Monday, December 1, 2025 For more than two decades, physician-scientist Omar Abdel-Wahab, MD , has been known around Memorial Sloan Kettering Cancer Center (MSK) for his insight, knowledge, and creativity as a cancer researcher.   Now he will also be known as a Paul Marks Prize winner , the first recipient

Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

… Thursday, May 15, 2025 Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with  Joan Massagué

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

Learn from MSK experts about how to quit smoking if you have cancer. It starts with having honest conversations about smoking and nicotine addiction.

… Friday, April 5, 2019 Summary Four MSK experts share strategies specifically for people with cancer to help them quit smoking. Most people know that smoking is the leading cause of cancer. But there is much less awareness among people with cancer — and their doctors — that smoking is associated with

Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced cancer care services, closer to home.

… Monday, January 31, 2011 Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced

Despite the promise of eventually using artificial intelligence to detect melanoma, much more research and development are needed, MSK experts find.

… Thursday, May 19, 2022 When it comes to smartphone technologies, today there’s an app for just about everything: You can play chess, learn to speak Mandarin, or map the best driving route to the airport. Health is a huge category for apps, but many of these programs don’t have the science to back their

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

… Wednesday, January 23, 2019 Summary Studying mutational changes that occur in brain tumors has been difficult. A new approach involves analyzing cancer DNA that the tumor sheds into the fluid surrounding the brain and spinal cord. This fluid can be collected in biopsies to help with diagnosis and choosing

The $50 million donation from Mike and Maria Repole and the Nonna’s Garden Foundation will support cancer care on Long Island and significantly advance research efforts.

… Monday, November 8, 2021 Memorial Sloan Kettering Cancer Center (MSK) today announced a generous $50 million gift from Mike and Maria Repole and the Nonna’s Garden Foundation to establish The Nonna’s Garden Foundation Initiative for Cancer Care and Research at MSK. The initiative will support several

The Thrivers event at Memorial Sloan Kettering celebrates Bone Marrow Transplant recipients on their return to health.

… Thursday, October 4, 2018 Family at BMT Thriver event Around 700 people joined the 23rd annual celebration for blood and marrow transplant thrivers at 583 Park Avenue, an event space in New York City. Bridget Anderson When Bridget Anderson learned there were no donor matches for a transplant to treat